Safety and immunogenicity of live attenuated human–bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants1This study was presented, in part, in a poster session at the Fifth Rotavirus Vaccine Workshop held on October 16–17, 1995, at the Centers for Disease Control and Prevention in Atlanta, GA. Informed consent was obtained from adult volunteers and the parents or guardians of pediatric participants. The guidelines for human experimentation of the U.S. Department of Health and Human Services and those of Johns Hopkins University and Vanderbilt University were followed in the conduct of these clinical studies.1